Q2 FY2026 EarningsQ2 FY2026 missed consensus across bottom-line metrics, with a net loss of $35.0M compared to the $23.7M expected, driven by a $10.0M one-time milestone payment for CRB-701. Diluted EPS was -$1.81 vs. -$1.26 expected, reflecting higher-than-anticipated clinical development spending. Despite the earnings miss, the company maintains a solid cash position of $117.9M, providing a runway into 2028, with critical clinical data readouts for CRB-913 (obesity) and enrollment for TEMPO-1 (oncology) both slated for September 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Corbus Pharma(CRBP) the EBIT is -36.19 M (-88.96%), Miss estimate;the EPS is -1.81 (-25.69%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.04B88.96%
-0.02B28.58%
-0.01B60.38%
EPSMiss expectations
-1.8125.69%
-1.261112.42%
-0.548938.11%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf